2.3 Patient Education: ACS/ACR Guidelines, BSE, CBE, Dose, and Modalities

Education without overstepping the order

Patients arrive with headlines: 'I heard I do not need a mammogram until 50,' 'My friend gets one every other year,' 'Can I just have an ultrasound so there is no radiation?' The mammography technologist's job is to explain the exam in front of her, state published guidelines accurately, and not independently change the interval the ordering clinician selected. ARRT's Patient Communication subdomain names ACS and ACR. Know those two cold. Know USPSTF 2024 well enough to recognize it on a 'which guideline' item, then return to ACS/ACR.

You are not the prescribing clinician. A useful close is: 'Different organizations publish different schedules. Your provider ordered a screening mammogram today. I can tell you what ACS and ACR currently say, and what we will do in this room.'

American Cancer Society (average risk)

ACS still publishes the 2015 average-risk framework on its patient pages, and that is the set to teach:

• Ages 40–44: opportunity to begin annual screening mammography if the patient wishes, after considering benefits and harms.
• Ages 45–54: annual mammography.
• Age 55 and older: transition to every other year, or continue annual screening—patient choice.
• When to stop: continue as long as the woman is in good health and has a life expectancy of at least 10 years. ACS does not set a hard stop age such as 74 or 75.

Clinical breast exam (CBE). ACS does not recommend CBE for breast cancer screening among average-risk women at any age. That is a high-yield contrast with older teaching and with some other organizations.

Breast self-exam (BSE). ACS does not present a prescribed monthly BSE technique as an average-risk screening method. Self-exams and clinical exams are described as not sufficient to find cancer early in average-risk people. What ACS does emphasize is breast awareness: know how the breasts normally look and feel, and report a change (lump, skin or nipple change, new inversion, spontaneous discharge) to a provider promptly. Cancers that present with symptoms are often found during ordinary activities such as bathing or dressing, not during a ritualized seventh-day-of-the-cycle exam.

High risk (ACS, patient-education level). Women at high risk (for example certain gene mutations, strong family history as defined by ACS, or chest radiation at a young age) are advised to have breast MRI and mammography every year, typically starting at age 30. MRI is in addition to, not instead of, mammography in that setting.

American College of Radiology

ACR's message to patients and referring clinicians is simpler on the average-risk start date and more aggressive on risk stratification:

• Average risk: annual screening mammography beginning at age 40.
• Risk assessment by age 25 for all women—especially Black women and women of Ashkenazi Jewish ancestry—so those who need earlier screening are identified before 40.
• Higher-than-average risk: earlier mammography (starting age varies by risk type, often in the 25–40 window) and supplemental breast MRI for many groups (genetics-based risk including BRCA1, calculated lifetime risk of 20% or more, chest radiation at a young age; MRI surveillance often beginning ages 25–30). Personal history of breast cancer diagnosed before 50, or personal history plus dense breasts, is another ACR setting for annual supplemental MRI. If MRI cannot be performed, contrast-enhanced mammography (CEM) may be considered; ultrasound is a complementary option when contrast-enhanced imaging is not available.

ACR does not treat MRI or ultrasound as a replacement for mammography in average-risk screening. Mammography (including digital breast tomosynthesis) remains the screening backbone because it depicts calcifications and is the modality with the strongest population screening evidence.

USPSTF 2024, in brief

The U.S. Preventive Services Task Force (2024) recommends biennial screening mammography for women ages 40–74 (Grade B). Evidence is insufficient to assess screening at 75 and older, and insufficient to recommend for or against supplemental ultrasound or MRI solely for dense breasts. USPSTF is the schedule patients quote from insurance and primary-care articles. It is not the same as ACS or ACR. When a stem says 'according to ACS' or 'according to ACR,' do not import the Task Force interval.

Memorize the table by the question you will actually get: Who says annual at 40? ACR (and ACS allows it at 40–44 but recommends annual at 45). Who says biennial at 55 as an option? ACS. Who says biennial 40–74? USPSTF 2024. Who dropped CBE for average-risk screening? ACS.

Dose: speak in AGD, not invented 'typical exam' numbers

Patients ask 'how much radiation is this?' Answer with concepts and a regulation, not a made-up milligray total for 'a normal mammogram.'

The relevant quantity is average glandular dose (AGD)—the dose to the glandular tissue that is at risk, not a skin entrance number from general radiography class. Individual AGD varies with compressed thickness and composition (more glandular tissue generally needs more exposure). AEC chooses the technique for the breast on the receptor; that is why two patients of the same age do not receive 'the same dose.'

What you can cite from federal rules: under MQSA (21 CFR 900.12(e)(5)(vi)), the AGD delivered during a single cranio-caudal view of an FDA-accepted phantom simulating a standard breast shall not exceed 3.0 mGy per exposure. That is a phantom / standard-breast limit, not a promise of the patient's personal four-view total. Do not convert 3.0 mGy into 'the exam is always 3 mGy' or into an airplane-flight equivalent unless your facility provides a reviewed script with a sourced number. Compression, which you already explained for image quality, also reduces thickness and is part of dose optimization.

Script (dose): 'This is a low-dose x-ray exam of the breast. Your dose depends on how thick the breast is when compressed and on how much glandular tissue you have. The machine automatically selects the exposure. Federal mammography rules cap the dose to a standard test phantom at 3.0 milligray per view. I do not have a single number that is every patient's dose.'

Modalities at a patient-education level

Two-dimensional full-field digital mammography (FFDM) is the familiar still picture in CC and MLO (plus extras as indicated).

Digital breast tomosynthesis (DBT, '3D') moves the tube through an arc and reconstructs thin slices so overlapping tissue is less likely to hide or mimic a mass. Many sites use DBT for screening, sometimes with a synthetic 2D reconstruction so a separate 2D exposure is not always added. Patient language: 'The machine will move and take a series of pictures so the radiologist can look through the breast in layers. You still need compression, and it is still a mammogram.'

Ultrasound is complementary. It is used to characterize a lump, to add information in dense tissue, and in many diagnostic pathways. It is not a stand-alone replacement for screening mammography in average-risk patients, because ultrasound does not replace mammography's ability to show calcifications and is not the ACS/ACR average-risk screening test.

Breast MRI is the high-risk adjunct (and, in ACR guidance, a supplemental tool in defined higher-risk or dense-breast settings). It requires contrast for screening/diagnostic breast MRI as usually performed. It is not the average-risk screening substitute: MRI can miss some calcifications that mammography shows, and average-risk MRI screening is not what ACS/ACR recommend in place of mammography.

Script (ultrasound request): 'Ultrasound is excellent for a lump or for extra looking in dense tissue, but it does not replace a mammogram for screening. Calcifications—the tiny specks that can be the first sign of some cancers—show on mammography. Your provider ordered a mammogram today for that reason.'

When the patient asks which guideline is 'right,' do not referee science in the hallway. Show the difference, name ACS and ACR as the two the credentialing exam emphasizes, and point her back to the ordering clinician for her interval. Your standard is an accurate explanation plus a completed, adequately compressed mammogram.